Molecular Insight Pharmaceuticals Company Profile: Acquisition & Investors

Molecular Insight Pharmaceuticals Overview

Founded
1998

Status
Acquired/Merged

Employees
71

Latest Deal Type
M&A

Financing Rounds
6

Molecular Insight Pharmaceuticals General Information

Description

Developer of small-molecule chemistry platform to significantly impact the care of men with prostate cancer. The company offers clinical stage specialty that are focused on critical unmet diagnostic and therapeutic needs of the prostate cancer patient.

Contact Information

Ownership Status

Acquired/Merged
(Operating Subsidiary)

Financing Status

Corporate Backed or Acquired

Primary Industry

Pharmaceuticals

Other Industries

Drug Discovery

Parent Company

Progenics Pharmaceuticals

Primary Office

160 Second Street
Cambridge, MA 02142
United States

+1 (617) 000-0000

Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Molecular Insight Pharmaceuticals Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Molecular Insight Pharmaceuticals‘s full profile, request access.

Request a free trial

Molecular Insight Pharmaceuticals Executive Team (10)

Name	Title	Board Seat	Contact Info
Nelson Stacks	Chief Executive Officer & Director
David Barlow	Chief Executive Officer & Chairman of Board
John Babich Ph.D	Chief Scientific Officer & President
Andrew Hilgenbrink	Director
Barry Frankel	Director

You’re viewing 5 of 10 executive team members. Get the full list »

Molecular Insight Pharmaceuticals Board Members (4)

Name	Representing	Role
00000 000000	Molecular Insight Pharmaceuticals	Chief Executive Officer & Chairman of Board
000000 000000	Self	Board Member
000000 000000000 00	Self	Board Member